EMAIL THIS PAGE TO A FRIEND

BMC medicine

Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury.


PMID 26286715

Abstract

Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI). Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and immune staining. Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network disruption in transfected cells. Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

235202
4-Bromomethyl-7-methoxycoumarin, 97%
C11H9BrO3
SAB1306569
ANTI-CYK18(C-TERMINAL) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4501665
Anti-Keratin 18, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4300551
Anti-KRT18 (Ab-33) antibody produced in rabbit, affinity isolated antibody
AV40205
Anti-KRT18 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV40206
Anti-KRT18 (AB2) antibody produced in rabbit, IgG fraction of antiserum
GW22753 Anti-KRT18 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB2701928
Anti-krt18 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SRP4817 Keratin-8 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
SAB3300015
Monoclonal Anti-CK18 antibody produced in mouse, clone 10, purified immunoglobulin, buffered aqueous glycerol solution
SAB3300017 Monoclonal Anti-CK18 antibody produced in mouse, clone 1H10, purified immunoglobulin, buffered aqueous glycerol solution
SAB1305526
MONOCLONAL ANTI-CYK18 (C-TERMINAL) antibody produced in mouse, clone 695CT17.2.6, crude ascites, buffered aqueous solution
SAB1305562
MONOCLONAL ANTI-CYK18(C-TERMINAL) antibody produced in mouse, clone 695CT17.2.6, IgG fraction of antiserum, buffered aqueous solution
WH0003875M1
Monoclonal Anti-KRT18 antibody produced in mouse, clone 2F8, purified immunoglobulin, buffered aqueous solution
SAB1404012
Monoclonal Anti-KRT18 antibody produced in mouse, clone 1G8, purified immunoglobulin, buffered aqueous solution
SAB4700411
Monoclonal Anti-KRT18 antibody produced in mouse, clone C-04, purified immunoglobulin, buffered aqueous solution
SAB4700670 Monoclonal Anti-KRT18 antibody produced in mouse, clone DC-10, purified immunoglobulin, buffered aqueous solution